- IXICO, the brain health company, reports revenues for the year to the end of September of £3.1 million and other income at £1.0 million, in line with market expectations, giving combined total income of £4.1 million.

This compares to £4.3 million of total income (£3.4 million of revenue and £0.9 million of other income) for the 16 month period to 30 September 2014.

Revenues in the year were achieved in the clinical trials business, including new contracts in Huntington's Disease, together with initial revenues from the Company's proprietary digital healthcare platform.

Operating expenses have been tightly controlled which has contributed towards a net cash figure at 30 September 2015 of £1.92 million which is ahead of market expectations and reflects a modest reduction from the net cash figure of £1.95 million at 31 March 2015. Post the year end, the company says it was pleased to announce a strategic collaboration with a leading pharmaceutical company to develop and pilot an adapted version of Assessa for the clinical management of multiple sclerosis. This collaboration is expected to make a material contribution to the company's revenues in the next 12-18 months which, together with the Phase II global clinical study in neurodegenerative disease announced in August, underpins the board's confidence in meeting current market expectations.

The Company anticipates that its preliminary results to 30 September will be announced in December.

Story provided by